Animal model of human disease. Multiple myeloma.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  American Journal of Pathology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 3414786PMCID PMC1880745
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow.

  1987cited by this paper
• The physiology of B cells as studied with tumor models.

  1986cited by this paper
• Influence of treatment with APD‐bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma

  1985cited by this paper
• Experimental immunoproliferative diseases. Models for immune responses and tumorigenesis.

  1984cited by this paper
• Animal model of human disease. Benign monoclonal gammopathy (idiopathic paraproteinemia).

  1981cited by this paper
• Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice.

  1979cited by this paper

• Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells

  2026cites this paper
• lncRNA H19 plays a role in multiple myeloma via interacting with hnRNPA2B1 to stabilize BET proteins by targeting osteoclasts and osteoblasts.

  2024cites this paper
• Interferon gamma‐mediated prevention of tumor progression in a mouse model of multiple myeloma

  2024cites this paper
• Current and Future PET Imaging for Multiple Myeloma

  2023cites this paper
• The Role of Bone Marrow Biopsy Evaluation in the Workup for Monoclonal Gammopathy of Renal Significance: A Diagnosis of Exclusion.

  2023cites this paper
• Immune-mediated tumor control in the 5TGM1 transfer model of multiple myeloma

  2023cites this paper
• Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction

  2022cites this paper
• Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine—Are We There Yet?

  2022cites this paper
• An indium-111-labelled membrane-targeted peptide for cell tracking with radionuclide imaging

  2022cites this paper
• In vivo models used in studies of bone metastases

  2022cites this paper
• Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity

  2021cites this paper
• Animal Models of Multiple Myeloma Bone Disease

  2021cites this paper
• Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model

  2021cites this paper
• Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies

  2021cites this paper
• Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma

  2021cites this paper
• Laboratory Mice – A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma

  2021cites this paper
• Current Understanding of Myelomatous Mesenchymal Stromal Cells Extended through Advances in Experimental Methods

  2020cites this paper
• Characterization of the role of Samsn1 loss in multiple myeloma development

  2020cites this paper
• An Improved Animal Model of Multiple Myeloma Bone Disease

  2020cites this paper
• GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice

  2020cites this paper
• Mouse tumor susceptibility genes identify drug combinations for multiple myeloma

  2020cites this paper
• Monoclonal glomerulopathy with features of cryoglobulinemic glomerulopathy in murine multiple myeloma model

  2020cites this paper
• Chronic intermittent hypoxia enhances disease progression in myeloma-resistant mice.

  2019cites this paper
• Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?

  2019cites this paper
• Myeloma Cells Down‐Regulate Adiponectin in Bone Marrow Adipocytes Via TNF‐Alpha

  2019cites this paper
• Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma

  2019cites this paper
• Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease

  2019cites this paper
• The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma

  2019cites this paper
• What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model

  2019cites this paper
• A Niche-Dependent Myeloid Transcriptome Signature Defines Dormant Myeloma Cells.

  2019cites this paper
• Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma

  2018cites this paper
• Evaluation of the biological activities of the IL‐15 superagonist complex, ALT‐803, following intravenous versus subcutaneous administration in murine models

  2018cites this paper
• Decreased JMJD3 expression in mesenchymal stem cells contributes to longterm suppression of osteoblast differentiation in multiple myeloma

  2018cites this paper
• Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo

  2018cites this paper
• Synthesis of C-functionalized TE1PA and comparison with its analogues. An example of bioconjugation on 9E7.4 mAb for multiple myeloma 64Cu-PET imaging.

  2018cites this paper
• Transient Lymphodepletion to Treat Death Receptor Ligand-1 Blockade after Programmed Death Receptor-1/Programmed

  2017cites this paper
• Sn2 lipase labile prodrugs and contact-facilitated drug delivery for lipid-encapsulated nanomedicines

  2017cites this paper
• Genetic Deletion of Sost or Pharmacological Inhibition of Sclerostin Prevent Multiple Myeloma-induced Bone Disease without Affecting Tumor Growth

  2017cites this paper
• Altered bone microarchitecture and gene expression profile due to calcium deficiency in a mouse model of myeloma.

  2017cites this paper
• Innovative Radiopharmaceuticals in Oncology and Neurology

  2017cites this paper
• Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.

  2017cites this paper
• Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses.

  2016cites this paper
• Low intensity vibration mitigates tumor progression and protects bone quantity and quality in a murine model of myeloma.

  2016cites this paper
• Preclinical animal models of multiple myeloma.

  2016cites this paper
• Therapeutic targeting of N‐cadherin is an effective treatment for multiple myeloma

  2015cites this paper
• Chapter 43 – In vivo models used in studies of bone metastases

  2015cites this paper
• New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative.

  2015cites this paper
• PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma

  2015cites this paper
• Correction: New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative.

  2015cites this paper
• Animal Models of Bone Metastasis

  2015cites this paper
• Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery

  2015cites this paper
• PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

  2015cites this paper
• Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model

  2015cites this paper
• Mouse Models to Study Obesity Effects on Hematologic Malignancies

  2015cites this paper
• Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction

  2015cites this paper
• Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells

  2014cites this paper
• Risk of Multiple Myeloma in Rheumatoid Arthritis: A Meta-Analysis of Case-Control and Cohort Studies

  2014cites this paper
• Cellular immunotherapy in multiple myeloma: lessons from preclinical models.

  2014cites this paper
• long-term in vivo cell tracking

  2014cites this paper
• Circulation of Passively Immunized Mice Extends Virus Persistence in Blood PEGylation of Vesicular Stomatitis Virus

  2014cites this paper
• Long lived PET tracers for tracking labelled cells

  2014cites this paper
• SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma12

  2014influential citation
• Diet-induced obesity promotes a myeloma-like condition in vivo

  2014cites this paper
• [89Zr]Oxinate4 for long-term in vivo cell tracking by positron emission tomography

  2014cites this paper
• PEGylation of Vesicular Stomatitis Virus Extends Virus Persistence in Blood Circulation of Passively Immunized Mice

  2013cites this paper
• Age matters:  Young T lymphocytes offer better protection from myeloma proliferation

  2013cites this paper
• Dynamics of tumor progression and therapy response in Il-6 and Myc driven plasma cell malignancy

  2013cites this paper
• Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma.

  2013cites this paper
• 213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma

  2013cites this paper
• Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors

  2013cites this paper
• multiple myeloma Osteoprotegerin inhibits the development of osteolytic bone disease in

  2013cites this paper
• Mathematical Model for Radial Expansion and Conflation of Intratumoral Infectious Centers Predicts Curative Oncolytic Virotherapy Parameters

  2013cites this paper
• CD45 heterogeneity Angiogenic switch during 5T2MM murine myeloma tumorigenesis; role of

  2013cites this paper
• Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma

  2013cites this paper
• MOLECULAR ASPECTS OF MULTIPLE MYELOMA MOLECULAIRE ASPEKTEN VAN HET MUL TIPEL MYELOOM

  2013cites this paper
• Novel In Vivo Models in Myeloma

  2013cites this paper
• osteoclast-stimulating activity 1-integrin enhances production of β 4 α VCAM-1 and cell contact between marrow stromal cells and myeloma cells via - Cell

  2013cites this paper
• Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma

  2012cites this paper
• Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models

  2012cites this paper
• Animal Models of Lymphoproliferative Disorders Focusing on Waldenström's Macroglobulinemia

  2012cites this paper
• Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.

  2012cites this paper
• Combination of Dasatinib and Dexamethasone targets the myeloma plasma cell through its interaction with the bone marrow microenvironment

  2012cites this paper
• Bone Marrow Stromal Cells Create a Permissive Microenvironment for Myeloma Development : A New Stromal Role for Wnt Inhibitor Dkk 1

  2012cites this paper
• Primary Neoplasms of Bones in Mice

  2012cites this paper
• A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic Disease

  2012cites this paper
• Immune Recovery after Cyclophosphamide Treatment in Multiple Myeloma: Implication for Maintenance Immunotherapy

  2011cites this paper
• Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells

  2011cites this paper
• Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.

  2011cites this paper
• Stem cell-based therapies in ischemic heart diseases: a focus on aspects of microcirculation and inflammation

  2011cites this paper
• Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade.

  2011cites this paper
• Chemoimmunotherapy Reduces the Progression of Multiple Myeloma in a Mouse Model

  2010cites this paper
• Small Animal Models for the Study of Cancer in Bone

  2010cites this paper
• Murine Models of Myeloma Bone Disease: The Importance of Choice

  2010cites this paper
• Anaplastic plasmacytomas: relationships to normal memory B cells and plasma cell neoplasms of immunodeficient and autoimmune mice

  2010cites this paper
• The role of the bone marrow microenvironment in the establishment and progression of multiple myeloma

  2010cites this paper
• Gr-1+CD11b+ Myeloid-Derived Suppressor Cells: Formidable Partners in Tumor Metastasis

  2010cites this paper
• Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy.

  2010influential citation
• In vivo Models Used in Studies of Bone Metastases

  2010cites this paper
• Features of Plasma Cell-Related Neoplasms in Mice

  2010cites this paper
• Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma‐Associated Bone Loss

  2009cites this paper